| pubmed-article:1932223 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1932223 | lifeskim:mentions | umls-concept:C0021757 | lld:lifeskim |
| pubmed-article:1932223 | lifeskim:mentions | umls-concept:C0079490 | lld:lifeskim |
| pubmed-article:1932223 | lifeskim:mentions | umls-concept:C1334117 | lld:lifeskim |
| pubmed-article:1932223 | lifeskim:mentions | umls-concept:C0344211 | lld:lifeskim |
| pubmed-article:1932223 | lifeskim:mentions | umls-concept:C0348080 | lld:lifeskim |
| pubmed-article:1932223 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:1932223 | pubmed:dateCreated | 1991-11-25 | lld:pubmed |
| pubmed-article:1932223 | pubmed:abstractText | A number of human hematopoietic growth factors have been genetically cloned and recombinant proteins produced. Several phase I and II clinical trials have already been published and results from phase III studies are becoming available. The use of erythropoietin to alleviate chemotherapy-induced myelosuppression is being tested. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor have been extensively studied in patients receiving chemotherapy at standard or escalated doses and after bone marrow transplantation and appear to ameliorate chemotherapy-induced neutropenia and to speed bone marrow engraftment after high-dose cancer therapy. Interleukin-3 and interleukin-6 are quite early in their clinical development, but appear able to alleviate post-chemotherapy thrombocytopenia. | lld:pubmed |
| pubmed-article:1932223 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1932223 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1932223 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1932223 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1932223 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1932223 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1932223 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:1932223 | pubmed:issn | 1040-8746 | lld:pubmed |
| pubmed-article:1932223 | pubmed:author | pubmed-author:SymannMM | lld:pubmed |
| pubmed-article:1932223 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1932223 | pubmed:volume | 3 | lld:pubmed |
| pubmed-article:1932223 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1932223 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1932223 | pubmed:pagination | 648-55 | lld:pubmed |
| pubmed-article:1932223 | pubmed:dateRevised | 2005-11-16 | lld:pubmed |
| pubmed-article:1932223 | pubmed:meshHeading | pubmed-meshheading:1932223-... | lld:pubmed |
| pubmed-article:1932223 | pubmed:meshHeading | pubmed-meshheading:1932223-... | lld:pubmed |
| pubmed-article:1932223 | pubmed:meshHeading | pubmed-meshheading:1932223-... | lld:pubmed |
| pubmed-article:1932223 | pubmed:meshHeading | pubmed-meshheading:1932223-... | lld:pubmed |
| pubmed-article:1932223 | pubmed:meshHeading | pubmed-meshheading:1932223-... | lld:pubmed |
| pubmed-article:1932223 | pubmed:meshHeading | pubmed-meshheading:1932223-... | lld:pubmed |
| pubmed-article:1932223 | pubmed:meshHeading | pubmed-meshheading:1932223-... | lld:pubmed |
| pubmed-article:1932223 | pubmed:meshHeading | pubmed-meshheading:1932223-... | lld:pubmed |
| pubmed-article:1932223 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:1932223 | pubmed:articleTitle | Hematopoietic growth factors as supportive therapy for cancer- and chemotherapy-induced conditions. | lld:pubmed |
| pubmed-article:1932223 | pubmed:affiliation | Catholic University of Louvain, Brussels, Belgium. | lld:pubmed |
| pubmed-article:1932223 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1932223 | pubmed:publicationType | Review | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1932223 | lld:pubmed |
